Loading...
XHKG0575
Market cap10mUSD
Dec 19, Last price  
0.37HKD
Name

Endurance RP Ltd

Chart & Performance

D1W1MN
XHKG:0575 chart
P/E
—
P/S
28.49
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.63%
Rev. gr., 5y
-42.58%
Revenues
382k
+991.43%
1,512,0003,425,0004,175,0003,684,0006,142,00020,553,0005,332,0004,669,0005,890,0002,670,000-10,000212,000137,0005,232,0006,120,000628,0001,320,0002,966,00035,000382,000
Net income
-25m
L-31.24%
5,088,000-41,892,0008,134,000612,000-160,943,00011,052,00059,792,000-48,527,000-44,854,000-25,636,000-8,563,000-9,333,000-2,460,000-27,359,000-31,087,000-65,999,000-24,396,000-12,598,000-36,427,000-25,049,000
CFO
-4m
L
-3,331,000-3,531,000-7,297,000-4,430,000-41,095,000-15,219,000-36,407,000-73,587,000-6,130,00052,654,000-3,984,000-7,732,000-8,307,000-2,747,000-1,882,000-9,038,000-5,721,000-1,703,000545,000-3,590,000
Dividend
Feb 08, 20130.0065 HKD/sh
Earnings
May 30, 2025

Profile

Endurance RP Limited, an investment holding company, holds investments in the healthcare and life sciences sectors in the People's Republic of China, Europe, Hong Kong, and Taiwan. The company operates in two segments, Biopharma and Corporate Investment. It engages in the research, development, manufacture, marketing, and sale of pharmaceutical products for the treatment and management of urological disorders; and development of artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. The company also invests in listed and unlisted corporate entities. In addition, it provides management and corporate finance services. The company was formerly known as Regent Pacific Group Limited and changed its name to Endurance RP Limited in June 2021. Endurance RP Limited was incorporated in 1991 and is headquartered in Central, Hong Kong.
URL
http://www.endurancerp.com/
IPO date
May 19, 1997
Employees
20
Domiciled in
HK
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
382
991.43%
35
-98.82%
2,966
124.70%
Cost of revenue
4,806
5,068
6,940
Unusual Expense (Income)
NOPBT
(4,424)
(5,033)
(3,974)
NOPBT Margin
Operating Taxes
(5,414)
419
(2,493)
Tax Rate
NOPAT
990
(5,452)
(1,481)
Net income
(25,049)
-31.24%
(36,427)
189.15%
(12,598)
-48.36%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,051
BB yield
Debt
Debt current
430
13,712
6,427
Long-term debt
1,940
320
8,367
Deferred revenue
18
7,282
Other long-term liabilities
(18)
(7,282)
Net debt
(45)
13,690
14,180
Cash flow
Cash from operating activities
(3,590)
545
(1,703)
CAPEX
(2)
(12)
(43)
Cash from investing activities
(1,000)
(7)
123
Cash from financing activities
5,582
(834)
(782)
FCF
(643)
5,002
(10,707)
Balance
Cash
2,415
1,438
11,127
Long term investments
(1,096)
(10,513)
Excess cash
2,396
340
466
Stockholders' equity
(306,211)
(291,734)
(253,292)
Invested Capital
305,855
308,061
306,071
ROIC
0.32%
ROCE
1,242.70%
EV
Common stock shares outstanding
225,103
119,993
119,971
Price
Market cap
EV
EBITDA
18,236
20,403
20,278
EV/EBITDA
Interest
80
1,013
1,218
Interest/NOPBT